4Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol, 2009, 20(4): 628- 635.
5Michael G, Nadia H, Christoph T. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel), 2011, 6(2): 136-141.
6Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
7Hugh J, Hanson J, Cheang MCU, et al. Breast cancer subtypes and response to docetaxel in node positive breast cancer; use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol, 2009, 27(8): 1168-1176.
8Zaha DC, Lazar E, Lazureanu C. Clinicopathologic features and five years survival analysis in mo]ecular subtypes of breast cancer. Rom J Morphol Embryol, 2010, 51(1): 85-89.
9Sodie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical impliications. Proe Natl Acad Sci USA, 2001, 98(19): 10869-10874.
10Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol, 2007, 18(1): 45-51.
